{"entity":{"id":"capmatinib-tepotinib","kind":"drug","name":"Capmatinib & tepotinib","aka":[],"tldr":"Capmatinib and tepotinib are two pills for the roughly 3% of lung cancers with a MET exon 14 skipping mutation.","summary":"Capmatinib and tepotinib are type Ib MET inhibitors that bind only the active conformation of the MET kinase, sparing other kinases. They treat the roughly 3% of non-small-cell lung cancers driven by a MET exon 14 skipping mutation, in both untreated and previously treated patients. Capmatinib (GEOMETRY mono-1: ORR 68% treatment-naive) was approved in 2020 with full approval in 2022; tepotinib (VISION: ORR ~57%) was approved in 2021 with full approval in 2024. Peripheral oedema is the class toxicity and often needs dose adjustment. MET amplification as an EGFR-TKI escape route is a different problem and is instead addressed by amivantamab and MET ADCs. The simple version: test lung adenocarcinomas for MET exon 14 skipping, because two pills work well when it is present.","status":"approved","asOf":"2026-09-06","wikipedia":"https://en.wikipedia.org/wiki/Capmatinib","links":[{"label":"FDA label (DailyMed)","url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Capmatinib%20%26%20tepotinib"}],"tags":[],"related":[],"cancers":["nsclc","met-altered-nsclc"],"sections":[],"technologies":["kinase-inhibitors"],"targets":["met"],"drugs":[],"companies":["novartis","merck"],"institutions":[],"pathways":[],"terms":[],"trials":["geometry-mono-1","nct02864992"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"brand":"Tabrecta / Tepmetko","modality":"Small-molecule kinase inhibitors (MET)","mechanism":"Highly selective type Ib MET inhibitors.","approvals":[{"region":"US","year":2020,"indication":"MET exon 14 skipping NSCLC (capmatinib; tepotinib 2021)"},{"region":"EU","year":2022,"indication":"Tepmetko 2022; Tabrecta 2022"}],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/capmatinib-tepotinib/","neighbours":{"cancer":[{"id":"met-altered-nsclc","kind":"cancer","name":"MET exon 14 and MET-amplified non-small-cell lung cancer","route":"/cancers/met-altered-nsclc/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"technology":[{"id":"kinase-inhibitors","kind":"technology","name":"Small-molecule kinase inhibitors","route":"/technologies/kinase-inhibitors/"}],"target":[{"id":"met","kind":"target","name":"MET","route":"/targets/met/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"},{"id":"merck-kgaa","kind":"company","name":"Merck KGaA (EMD Serono)","route":"/companies/merck-kgaa/"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/"}],"trial":[{"id":"geometry-mono-1","kind":"trial","name":"GEOMETRY mono-1","route":"/trials/geometry-mono-1/"},{"id":"nct02864992","kind":"trial","name":"VISION (tepotinib)","route":"/trials/nct02864992/"}],"person":[{"id":"juergen-wolf","kind":"person","name":"Jürgen Wolf","route":"/people/juergen-wolf/"}],"pathway":[{"id":"rtk-activation","kind":"pathway","name":"Receptor tyrosine kinase activation","route":"/pathways/rtk-activation/"}],"biomarker":[{"id":"met-ex14","kind":"biomarker","name":"MET exon 14 skipping mutation","route":"/biomarkers/met-ex14/"}]}}